Trader Books $13M Profit on “Nvidia of Crypto”

A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips.

Click here to review my research and the strategy I've developed for the opportunity to trade this c

PYC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 59.24%

Insider Buying (Last 12 Months): A$5,250,000.00

Insider Selling (Last 12 Months): A$0.00

PYC Therapeutics Insider Trading History Chart

PYC Therapeutics Share Price & Price History

A^$0.00

+0.30 (1.20%)

As of 01/1/2000 01:00 AM ET

Invest before this deal closes on 9/18

From Deal Maker | Ad

This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030. Invest before this investment round closes on 9/18.

Learn more about how you can become a shareholder before their planned Nasdaq listing

PYC Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/17/2024	Alan Tribe	Insider	Buy	50,000,000	A$0.11	A$5,250,000.00
6/29/2023	Alan Tribe	Insider	Buy	82,610	A$0.05	A$4,378.33
6/26/2023	Alan Tribe	Insider	Buy	1,590,767	A$0.05	A$84,310.65
8/10/2022	Alan Tribe	Insider	Buy	491,463	A$0.06	A$29,979.24
8/3/2022	Alan Tribe	Insider	Buy	1,683,537	A$0.06	A$102,695.76

You won’t believe what this ex-Wall Street insider discovered about the election

From Banyan Hill Publishing | Ad

One ex-Wall Street insider recently combed through 64 years of election data… And he just uncovered something surprising about the presidential elections… It turns out that for the past 64 years, the stock market has soared during election seasons - regardless of whether a Democrat or Republican is elected. In other words, if you're sitting on the sidelines because you're worried about how the market will react to a Trump or Kamala win, you could be missing out on some serious profits.

Learn all about it here.

SEC Filings (Institutional Ownership Changes) for PYC Therapeutics (ASX:PYC)

0.59% of PYC Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

9.46%

Beta

0.71

Who are the company insiders with the largest holdings of PYC Therapeutics?: PYC Therapeutics' top insider shareholders include:
Alan Tribe (Insider)
Learn More about top insider investors at PYC Therapeutics.